Citius Pharmaceuticals, Inc.
CTXR
$0.79
-$0.04-4.81%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 47.17% | -5.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 46.85% | -3.99% | |||
| Operating Income | -0.10% | 3.99% | |||
| Income Before Tax | -7.67% | 5.15% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | -7.44% | 5.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 49.55% | 89.47% | |||
| Net Income | -3.29% | 9.45% | |||
| EBIT | -0.10% | 3.99% | |||
| EBITDA | 6.69% | 3.99% | |||
| EPS Basic | 17.37% | 42.05% | |||
| Normalized Basic EPS | 26.02% | 44.15% | |||
| EPS Diluted | 17.37% | 42.05% | |||
| Normalized Diluted EPS | 26.02% | 44.15% | |||
| Average Basic Shares Outstanding | 24.97% | 56.26% | |||
| Average Diluted Shares Outstanding | 24.97% | 56.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||